Advent Life Sciences

Advent Life Sciences is one of Europe's leading venture teams investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences, principally in new drug discovery, enabling technologies, and med tech. Realisations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

Naseem Amin

Venture Partner

SB

Steve Butcher

Operating Partner

Don Drakeman

Venture Partner

MK

Mary Kerr

Operating Partner

SK

Simon Kerry

Operating Partner

LA

Laura A. Lane

Principal

Karen Larochelle

Venture Partner

Roy Lobb

Venture Partner

Kaasim Mahmood

General Partner

Shahzad Malik

General Partner

JM

Jon Moore

Operating Partner

Ian Nicholson

Operating Partner

Raj Parekh

General Partner

JR

John Rex

Operating Partner

Alan Walts

Venture Partner

141 past transactions

Vestagen Technical Textiles

Convertible Note in 2015
Vestagen Protective Technologies, Inc. develops and markets high performance healthcare textiles, lab coats, and uniforms for specialty healthcare workers, patients, and other occupations. The company sells its products directly, as well as through its retail partners and distributors. It also serves customers via online. Vestagen Protective Technologies, Inc. was formerly known as Vestagen Technical Textiles, Inc. The company was founded in 2009 and is based in Orlando, Florida.

Santarus

Series C in 2001
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

Qype

Series A in 2006
Qype is a social network based around user reviews of businesses and places. The site allows its users to browse a database of locations and see at a glance those which have been most favorably rated by the community. Members of the site can add new places to the existing database, rate and review businesses, add videos and photos and engage with the community via message boards, groups and messaging. Founded in 2005 by German entrepreneur Stephan Uhrenbacher, the site also has a mobile version which can enables users to locate the top rated place near to a specified location.

BridgeCo

Venture Round in 2009
BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Calcico Therapeutics

Venture Round in 2015
Calcico is a venture backed biotechnology company focused on the development of novel CRAC channel inhibitors. The company aims to develop selective small molecules to treat a range of inflammatory and autoimmune conditions where there is clear evidence linking CRAC to human disease. Calcico is an Oxford based start up which was formed in April 2012 and funded by Advent Life Sciences and Touchstone Innovations. The company has developed proprietary ‘know-how’ comprising novel systems for selective CRAC channel screening and molecule characterisation. This puts us in a unique position to achieve the goal of potent and selective CRAC channel inhibition, which has so far eluded pharmaceutical companies.

Avidex

Venture Round in 2012
Avidex is an award-winning, full service audiovisual firm. An innovative leader in the design, integration, project management, equipment procurement and support services of audiovisual solutions for commercial and healthcare clients throughout the U.S. Avidex also offers a broad range of equipment rental and show services. Avidex successfully partners with architects, contractors, consultants, educators and executives to create boardrooms, videoconference rooms, auditoriums, training facilities, digital signage and many additional projects that incorporate audiovisual needs. With a current staff of over 130 employees, the people at Avidex have the background and knowledge to provide you with the best possible experience in implementing audiovisual and multimedia technologies. Over the past 10 years Avidex has successfully completed many International jobs in more than a dozen different countries ranging from Europe to Asia and has completed jobs in over 26 states. Avidex is a true single source for all audiovisual needs.

Acutus Medical

Series C in 2016
Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

Oxagen

Series C in 2009
Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.

Farfetch

Series D in 2014
Farfetch operates an e-commerce website that unites various independent fashion boutiques. It offers bags, coats, dresses, jackets, jewellery, swimwear, trouser, shoes, knitwear, suits, shorts, and accessories. They operate a modular end-to-end technology platform purpose built to connect the luxury fashion ecosystem worldwide. Their vision was to create a single operating system that could address the complex demands of consumers and luxury sellers alike. Their platform is built on an API-enabled proprietary technology stack, which provides the foundation for the three main components: applications, services and data. Farfetch serves women, men, and kids. Jose Neves founded the company in 2008, with its headquarters in London, United Kingdom.

NeRRe Therapeutics

Series B in 2021
NeRRe Therapeutics Ltd. develops preclinical and clinical neurokinin (NK) receptor antagonists. The company focuses on NK-1 antagonist asset orvepitant as an oral treatment for intense pruritus induced by targeted anti-cancer therapies. It offers NT-814, a NK-1, 3 antagonist; NT-949, a Phase I ready NK-1 antagonist; and NT-432, a NK-1 antagonist clinical candidate. The company was founded in 2012 and is based in Stevenage, United Kingdom.

Nalu Medical

Venture Round in 2015
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

Biocartis Group NV

Series A in 2009
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.

WorldStores Limited

Series C in 2013
Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories. ACHICA, the luxury flash-sale business, and baby specialist Kiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market.

Wiz, Inc.

Series B in 2021
Wiz, Inc. designs and develops a cloud security platform for enterprises. The company’s platform provides enterprises with weighed risk assessment, root cause analysis, and a comprehensive representation of and insights about cloud infrastructure. The company was founded in 2020 and is based in Palo Alto, California with an additional office in Tel Aviv, Israel.

Adeptra

Series A in 1999
Adeptra Ltd. provides automated contact and resolution services to consumer credit and risk management companies. It offers Auto-resolution Services, which are two-way voice and alerting solutions to reach out and deliver customer communication through voice, fax, pagers, text messaging, and email; and Adeptra Analytics, an analytics platform that enables financial organizations to build consumer credit and risk management strategies. The company also provides industry-specific solutions for business processes, such as fraud detection, collections, and marketing. It serves financial institutions, card issuers, and banks, as well as mortgage lending, loan, and utility markets. The company has a strategic alliance with Fair Isaac Corporation. Adeptra Ltd. was formerly known as RealCall Ltd. The company was founded in 1996 and is headquartered in Reading, the United Kingdom. It has additional offices in Norwalk, Connecticut; and London, the United Kingdom, as well as in Sydney, Singapore, and Hong Kong.

Amphista Therapeutics

Series A in 2020
Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins.

KuDOS Pharmaceuticals Ltd

Series A in 1999
KuDOS Pharmaceuticals Ltd discovers and develops drugs based upon the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.

F2G

Venture Round in 2016
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.

Artax BioPharma Inc.

Series B in 2015
Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. Its lead product candidate includes IPI-504 (retaspimycin hydrochloride), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). The company is conducting an international Phase II clinical trial of IPI-504 in combination with Herceptin in patients with HER2-positive metastatic breast cancer; a Phase II clinical trial of IPI-504 in patients with advanced non-small cell lung cancer; and a Phase I clinical trial of IPI-504 in combination with Taxotere in patients with advanced solid tumors. Its products under Phase I clinical trial comprise IPI-493, an orally-delivered inhibitor of Hsp90, in patients with advanced solid tumors; IPI-926 for patients with advanced and/or metastatic solid tumors; and IPI-940, an orally-delivered inhibitor of fatty acid amide hydrolase for the treatment of neuropathic and inflammatory pain. Infinity Pharmaceuticals has strategic alliance agreements with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited; an agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway; and a collaboration agreement with Novartis Institute for BioMedical Research, Inc. to discover, develop, and commercialize drugs targeting Bcl protein family members for the treatment of cancers. The company is headquartered in Cambridge, Massachusetts.

Rappta Therapeutics Oy

Series A in 2020
Rappta Therapeutics Oy engages in developing anti-cancer drugs that activate protein phosphatase 2A (PP2A). Protein phosphatase 2A (PP2A) is a critical enzyme regulating protein de-phosphorylation and tumor growth. The company was incorporated in 2019 and is based in Helsinki, Finland with an additional office in the United States.

Nalu Medical

Venture Round in 2022
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

Artax BioPharma Inc.

Venture Round in 2022
Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Ubiquisys

Venture Round in 2012
Ubiquisys is a mobile communications company that designs and develops communications devices for mobile operators and consumers. It provides ZoneGate femtocell system, a small plug-and-play device that plugs into home or office broadband connection and provides 3G coverage in the home and office, as well as supports various mobile services. The company also offers convergence solutions to the wireless-wireline convergence technology market.

Levicept

Series A in 2014
With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability. Levicept is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. We are progressing LEVI-04 to phase I clinical trials to test its efficacy and safety in patients with osteoarthritis.

MiroBio Ltd

Series B in 2022
MiroBio Ltd develops and manufactures antibody modulators of immune cell receptors for auto-immune diseases. The company is developing antibodies and variants to stimulate specific immune cell signals to harness the natural control mechanisms of the immune system. The company was incorporated in 2018 and is headquartered in Oxford, United Kingdom.

CN Creative

Series A in 2012
Headquartered in the Bioscience Incubator at Manchester University in the UK, CN Creative provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. It has developed a distinctive portfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. CNC's diverse products include QuitDirect, an NHS-accredited supplier of comprehensive smoking cessation services, the Intellicig® electronic cigarette, ECOpure proprietary high purity nicotine preparations and NRT Direct, which provides traditional nicotine replacement therapy products and patient support services to publicly and privately sponsored smoking cessation programmes. CNC's Nicadex(TM) electronic inhaler nicotine replacement therapy product is in clinical development for use as part of medically supervised smoking cessation programmes.

WorldStores Limited

Series D in 2015
Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories. ACHICA, the luxury flash-sale business, and baby specialist Kiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market.

Acutus Medical

Series B in 2013
Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

BridgeCo

Venture Round in 2007
BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Vestagen Technical Textiles

Venture Round in 2013
Vestagen Protective Technologies, Inc. develops and markets high performance healthcare textiles, lab coats, and uniforms for specialty healthcare workers, patients, and other occupations. The company sells its products directly, as well as through its retail partners and distributors. It also serves customers via online. Vestagen Protective Technologies, Inc. was formerly known as Vestagen Technical Textiles, Inc. The company was founded in 2009 and is based in Orlando, Florida.

OpenCloud Limited

Venture Round in 2010
OpenCloud, formed in 2000 is a privately funded company. It provides the telecommunications industry with a real-time Application Server for agile development, deployment and efficient management of person-to-person communications services across current and next generation network technology.

Radiant Networks Plc

Series C in 2002
Radiant Networks develops a broadband fixed wireless access technology solution. Its solution has network deployments in Europe and the United States.

Celoxica

Venture Round in 2007
Based in London, United Kingdom, Celoxica delivers latency market data access and order execution solutions to the advanced trading community. The company’s solutions include a full range of market data feed handlers for the main U.S. and European equities, options, futures exchanges, and FX. With clients that include trading firms who co-locate their strategic applications in high frequency trading environments, market making, liquidity provision, algorithmic trading, and smart order routing, the company also offers a single access point for brokers and their clients by handling inbound FIX, credit check, and outbound native protocol to the execution venues. Celoxica was founded in 1996.

Ubiquisys

Series A in 2006
Ubiquisys is a mobile communications company that designs and develops communications devices for mobile operators and consumers. It provides ZoneGate femtocell system, a small plug-and-play device that plugs into home or office broadband connection and provides 3G coverage in the home and office, as well as supports various mobile services. The company also offers convergence solutions to the wireless-wireline convergence technology market.

AmberFin

Venture Round in 2010
AmberFin enables content owners to maximize the value of their TV, film and video content, from capture through to distribution, while increasing revenues, reducing costs, saving time and eliminating incompatibility issues. AmberFin iCR, with four-time Emmy-award winning technology, plays a key role in turning the content that owners have into the content their customers want. As an open standards, future proof platform that digitizes and transforms new and archived content, AmberFin iCR delivers the best quality pictures at smaller file sizes across multiple delivery platforms, including the Internet, VoD, TV, mobile and other small screen devices.

Algeta

Series A in 2005
Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA was founded in 1997 and is headquartered in Oslo, Norway.

Pertinence Data Intelligence

Venture Round in 2004
Pertinence is a global leader in Enterprise Manufacturing Intelligence software, enabling the extraction, application, control, and sharing of Best Operational Practices (BOPs). Pertinence develops software dedicated to optimizing industrial processes and complex systems. Through its innovative, leading-edge data analysis technology, Pertinence empowers professionals to improve process quality, reduce time to market for product launches and better manage complex systems' initial set up. Pertinence, a Microsoft Certified Partner, is located in Europe and the United States, and customers include industry leaders from the Pharma-Biotech, Aerospace and Defense and Industrial Products sectors, including Airbus, BMW, Sanofi Pasteur, Siemens, etc.

Vitrue

Series C in 2011
Vitrue offers the industry’s most scalable and secure cloud-based social marketing solution, enabling brands to harness the full marketing potential of social on Facebook, Twitter, Google+, YouTube and emerging platforms. The award-winning Vitrue SRM platform collectively manages more than one billion social relationships in over 100 countries across more than 4,500 social accounts for its clients. For more information, visit www.vitrue.com.

TandemLife

Venture Round in 2001
TandemLife develops, manufactures, and markets innovative medical device products to provide Cardiologists and Cardiac Surgeons from around the world with unique solutions for patients requiring circulatory support. The FDA-cleared TandemHeart® System delivers extracorporeal circulatory support in just minutes... not hours. Used by cardiologists in the cath lab and by cardiac surgeons in the OR (operating room), TandemHeart® can provide up to 5.0 lpm of circulatory support when used percutaneously, and up to 8.0 lpm of circulatory support with a direct surgical cannulation method. TandemHeart® is comprised of three major sub-systems: (1) the TandemHeart® Pump provides circulating power to pull oxygenated blood from the left atrium and to return it to the systemic arterial circulation; (2) the TandemHeart® Cannulae Set connects the pump to the body by way of two percutaneous access points in the patient’s groin; and (3) the TandemHeart® Controllers provide operating power to the pump, provides a controlled flow of lubricant to the pump, and also provides automatic system-monitoring and alarms that indicate conditions which require immediate attention

Arrakis Therapeutics

Series A in 2017
Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care.

OpenCloud Limited

Series A in 2007
OpenCloud, formed in 2000 is a privately funded company. It provides the telecommunications industry with a real-time Application Server for agile development, deployment and efficient management of person-to-person communications services across current and next generation network technology.

Network365

Series C in 2003
Network365, a leading provider of mobile commerce software products.

NeRRe Therapeutics

Series B in 2017
NeRRe Therapeutics Ltd. develops preclinical and clinical neurokinin (NK) receptor antagonists. The company focuses on NK-1 antagonist asset orvepitant as an oral treatment for intense pruritus induced by targeted anti-cancer therapies. It offers NT-814, a NK-1, 3 antagonist; NT-949, a Phase I ready NK-1 antagonist; and NT-432, a NK-1 antagonist clinical candidate. The company was founded in 2012 and is based in Stevenage, United Kingdom.

EUSA Pharma, Inc.

Venture Round in 2008
Founded in March 2015, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Farfetch

Series A in 2010
Farfetch operates an e-commerce website that unites various independent fashion boutiques. It offers bags, coats, dresses, jackets, jewellery, swimwear, trouser, shoes, knitwear, suits, shorts, and accessories. They operate a modular end-to-end technology platform purpose built to connect the luxury fashion ecosystem worldwide. Their vision was to create a single operating system that could address the complex demands of consumers and luxury sellers alike. Their platform is built on an API-enabled proprietary technology stack, which provides the foundation for the three main components: applications, services and data. Farfetch serves women, men, and kids. Jose Neves founded the company in 2008, with its headquarters in London, United Kingdom.

MiroBio Ltd

Series A in 2019
MiroBio Ltd develops and manufactures antibody modulators of immune cell receptors for auto-immune diseases. The company is developing antibodies and variants to stimulate specific immune cell signals to harness the natural control mechanisms of the immune system. The company was incorporated in 2018 and is headquartered in Oxford, United Kingdom.

Moximed

Series C in 2022
Moximed, Inc. develops a joint preserving option for patients with knee osteoarthritis. The company offers Atlas System, an implantable joint unloader that works like a shock absorber for a patient with medial compartment knee osteoarthritis, or suffering from pain on the medial (inner) side of the knee, or desire to maintain high activity or productivity levels. It serves patients and medical professionals worldwide. Moximed, Inc. was formerly known as ExploraMed NC4, Inc. The company was incorporated in 2006 and is based in Hayward, California.

Prexa Pharmaceuticals

Series B in 2011
Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.

Microscience

Series C in 2002
Microscience is a biotechnology company focussed on the discovery and development of innovative rationally designed vaccines for the prophylaxis and treatment of disease in areas of significant unmet clinical need. Microscience, which was founded in 1997, has used proprietary functional genomics and vaccine technology expertise as the basis of an expanding product portfolio. The Company’s secure intellectual property – with three granted patents and many others covering over 300 genes and targets – underpins the product development, providing long-term intellectual property protection well beyond the projected product launch dates.

Aura Biosciences, Inc.

Venture Round in 2021
Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

Biospect

Series B in 2003
Biospect, Inc. is developing minimally invasive technology for identifying and assaying protein biomarker patterns that reflect and differentiate biological states. The integrated Biospect system consists of proprietary separations, detection and informatics technologies, and is targeted for use in diagnosing and managing disease or drug development. Biospect is backed by Advent Venture Partners, Prospect Venture Partners, Venrock Associates and Versant Ventures and was incubated by Prospect Venture Partners.

Amphista Therapeutics

Series B in 2021
Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins.

Cellnovo Group SA

Series A in 2008
They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition. The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.

Macrolide Pharmaceuticals

Venture Round in 2018
Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others, especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides. The company was founded in 2014 and is headquartered in Newton, Massachusetts.

Eqos

Venture Round in 2000
Eqos is a software development company that specializes in e-collaboration software. It develops and supplies collaborative supplier management and sourcing solutions with a specific focus on the retail sector. The company was founded in1997 and is headquartered in Leatherhead, Surrey.

Vestagen Technical Textiles

Venture Round in 2016
Vestagen Protective Technologies, Inc. develops and markets high performance healthcare textiles, lab coats, and uniforms for specialty healthcare workers, patients, and other occupations. The company sells its products directly, as well as through its retail partners and distributors. It also serves customers via online. Vestagen Protective Technologies, Inc. was formerly known as Vestagen Technical Textiles, Inc. The company was founded in 2009 and is based in Orlando, Florida.

K2 Optronics

Series C in 2004
K2 Optronics specializes in designing, developing, and manufacturing analog and digital transmission lasers for the cable television (CATV), telecommunications, sensing, and test and measurement industries.

Conatus Pharmaceuticals

Series B in 2011
Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to date its development has been the primary focus of the Company.

Macrolide Pharmaceuticals

Series A in 2020
Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others, especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides. The company was founded in 2014 and is headquartered in Newton, Massachusetts.

Pathwork Diagnostics

Series C in 2010
Pathwork Diagnostics is based in Redwood City, California. The company develops and delivers innovative molecular diagnostics for oncology. The Pathwork Tissue of Origin Test for frozen tissue was the first to receive FDA clearance for a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastic cancer.

F2G

Venture Round in 2020
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.
Vestagen Protective Technologies, Inc. develops and markets high performance healthcare textiles, lab coats, and uniforms for specialty healthcare workers, patients, and other occupations. The company sells its products directly, as well as through its retail partners and distributors. It also serves customers via online. Vestagen Protective Technologies, Inc. was formerly known as Vestagen Technical Textiles, Inc. The company was founded in 2009 and is based in Orlando, Florida.
CardiAQ Valve Technologies (CVT), a privately held company, is developing innovative approaches to heart valve replacement and is initially focused on transcatheter mitral valve implantation (TMVI).

Cellnovo Group SA

Series B in 2011
They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition. The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.

Foundry

Acquisition in 2009
With a 20-year heritage and a portfolio of award-winning products, Foundry advances the art and technology of visual experience in partnership with creative leaders around the globe. Our products are used to create breathtaking visual effects sequences on a wide range of feature films, video-on-demand, television and commercials.

K2 Optronics

Series B in 2001
K2 Optronics specializes in designing, developing, and manufacturing analog and digital transmission lasers for the cable television (CATV), telecommunications, sensing, and test and measurement industries.

Oxagen

Series B in 2005
Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.

Audium Semiconductor

Series A in 2007
Audium is a fabless semiconductor company developing innovative, highly efficient audio power amplifier products for the Consumer Electronics market. The company was founded in March 2006 by Clyde Witchard and Huw Davies and is headquartered in Bristol, U.K.

Vestagen Technical Textiles

Venture Round in 2017
Vestagen Protective Technologies, Inc. develops and markets high performance healthcare textiles, lab coats, and uniforms for specialty healthcare workers, patients, and other occupations. The company sells its products directly, as well as through its retail partners and distributors. It also serves customers via online. Vestagen Protective Technologies, Inc. was formerly known as Vestagen Technical Textiles, Inc. The company was founded in 2009 and is based in Orlando, Florida.

Celoxica

Series D in 2001
Based in London, United Kingdom, Celoxica delivers latency market data access and order execution solutions to the advanced trading community. The company’s solutions include a full range of market data feed handlers for the main U.S. and European equities, options, futures exchanges, and FX. With clients that include trading firms who co-locate their strategic applications in high frequency trading environments, market making, liquidity provision, algorithmic trading, and smart order routing, the company also offers a single access point for brokers and their clients by handling inbound FIX, credit check, and outbound native protocol to the execution venues. Celoxica was founded in 1996.

Farfetch

Series B in 2012
Farfetch operates an e-commerce website that unites various independent fashion boutiques. It offers bags, coats, dresses, jackets, jewellery, swimwear, trouser, shoes, knitwear, suits, shorts, and accessories. They operate a modular end-to-end technology platform purpose built to connect the luxury fashion ecosystem worldwide. Their vision was to create a single operating system that could address the complex demands of consumers and luxury sellers alike. Their platform is built on an API-enabled proprietary technology stack, which provides the foundation for the three main components: applications, services and data. Farfetch serves women, men, and kids. Jose Neves founded the company in 2008, with its headquarters in London, United Kingdom.

WorldStores Limited

Debt Financing in 2011
Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories. ACHICA, the luxury flash-sale business, and baby specialist Kiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market.

F2G

Venture Round in 2012
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.

Dailymotion

Series C in 2009
The biggest independent video sharing website in the world

Southampton Photonics

Series B in 2003
Southampton Photonics Ltd., a U.K. startup. The company, with origins at Southampton University's Optical Research Center (ORC), aims to establish itself in the design and manufacture of fiber-optic components for the dense wave-division multiplexing (DWDM) and optical telecommunications market using technology from the university.

Aleta Biotherapeutics, Inc.

Venture Round in 2016
Aleta Biotherapeutics, Inc. transforms cellular therapeutics to allow a broader spectrum of cancer indications. The company was founded in 2015 and is based in Natick, Massachusetts.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Versartis

Series B in 2011
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Phyworks

Series B in 2003
Phyworks' analog and mixed signal ICs bring ultra high-performance to optical fiber and copper cable communications in datacom, storage and telecom systems throughout the world.

Aura Biosciences, Inc.

Series B in 2015
Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

Echovox

Series B in 2007
Founded in 2000, Echovox has built a unique gateway infrastructure offering premium SMS, Bulk and WAP billing in more than 20 different countries, connecting more than 100 mobile carriers worldwide and covering over 500 million subscribers. As an established leader in the mobile monetization space, Echovox enables large media companies, leading web players, mobile content providers and application developers to monetize their traffic though mobile transactions. Echovox was venture-backed by Advent Venture Partners and Newbury Ventures and launched Zong, world’s leading mobile payment solution, sold to Paypal in 2011. Strong of a 15 year experience in the mobile payment industry, our platform ECHONECTTM provides the best unified interface to the mobile world.

PIC Therapeutics, Inc.

Seed Round in 2020
PIC Therapeutics, Inc. engages in the development of therapeutics based on the modulation of ribonucleic acid translation to treat cancer. The company’s therapeutics target the master switch of cancer signaling pathways, selectively blocking oncogene protein production by modulating the pre-initiation complex that drives the messenger RNA translation. PIC Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Riskclick

Series C in 2005
Riskclick, Inc. develops underwriting software solutions for property and casualty insurers. Its products include Riskclick Underwriting Process Manager, a rules- and referral-driven underwriting application with agent and broker servicing features; and The Riskclick Underwriting Process Manager Toolkit, which configures the Underwriting Process Manager. The company also provides process definition, data libraries, user screens, web services mapping, underwriting rules, testing, and installation services. Riskclick, Inc. was incorporated in 2000 and is headquartered in New York, New York.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

The Fizzback Group

Venture Round in 2007
The Fizzback Group are innovators in customer engagement. Founded in 2004, the award-winning Fizzback solution helps companies to listen, respond, and act in real-time to their customers' comments. Feedback captured at the point of experience is analyzed automatically using a unique artificial intelligence engine, driving relevant responses, prompting company action and providing powerful insight into the voice of a previously silent majority. Fizzback enables businesses to derive true economic benefits by increasing customer lifetime value and positive word-of-mouth.

Aura Biosciences, Inc.

Series C in 2017
Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

Avila Therapeutics

Series A in 2007
Avila Therapeutics, Inc. designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics, Inc. has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics, Inc. operates as a subsidiary of Celgene Corporation.

Conatus Pharmaceuticals

Series A in 2007
Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to date its development has been the primary focus of the Company.

Ubiquisys

Venture Round in 2010
Ubiquisys is a mobile communications company that designs and develops communications devices for mobile operators and consumers. It provides ZoneGate femtocell system, a small plug-and-play device that plugs into home or office broadband connection and provides 3G coverage in the home and office, as well as supports various mobile services. The company also offers convergence solutions to the wireless-wireline convergence technology market.
KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.

Versartis

Series C in 2013
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Acutus Medical

Series D in 2019
Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

Versartis

Series C in 2013
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Versartis

Series D in 2013
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

BridgeCo

Series D in 2006
BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Versartis

Series E in 2014
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Dailymotion

Series B in 2007
The biggest independent video sharing website in the world

Thiakis

Series A in 2006
Thiakis Limited with a focus on developing novel medicines for the treatment of obesity and co-morbidities based on original research conducted by Professor Steve Bloom and his colleagues at Imperial College London.

Orecon

Series A in 2008
Wave energy is the future and Orecon is making that future today's reality. The oceans are a source of immense and limitless power. Orecon is here to harness that power and convert it into sustainable and affordable electricity. Orecon's MRC has been designed specifically to do this. It's a robust and reliable wave energy device that uses the best tried and tested components on the market. And it's clean because respecting the oceans is as important to us as releasing the power within them.

Bioncotech

Venture Round in 2021
Bioncotech is a development stage bio-pharma company focused on the development of a new concept of anticancer therapy for the treatment of tumors such as metastatic melanoma, glioblastoma, bladder, or pancreatic cancer. The company is a spin-off of the Spanish National Cancer Research Centre, one of the leading international centers in cancer research. It Therapeutics is a biopharmaceutical company dedicated to the development of new oncologic treatments. The company develops and manages projects throughout the value-creation chain: from formulation, manufacturing, and preclinical development to clinical trials with the support of other institutions and pharmaceutical companies. Founded in 2012 by [Maria Gonzalez](https://www.crunchbase.com/person/maria-gonzalez-2), Bioncotech is headquartered in Paterna with other designations in Madrid, Spain and Cambridge, Massachusetts.

Pelikon

Series C in 2003
Pelikon, Ltd. provides morphing keypad solutions. It offers animated backlites and panels, as well as display products. The company also provides liquid crystal displays, display drivers, and display controllers. Its products are used in various applications, such as portable devices, home appliances, control panels, fitness equipment, and mobile phones. Pelikon, Ltd. was formerly known as Elumin, Ltd. The company was incorporated in 1999 and is based in Cambridge, the United Kingdom. It has sales offices in North America, China, and Japan. As of December 10, 2008, Pelikon Ltd. operates as a subsidiary of Multi-Fineline Electronix Singapore Pte., Ltd.

Conatus Pharmaceuticals

Venture Round in 2006
Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to date its development has been the primary focus of the Company.

Acutus Medical

Series A in 2011
Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

NeoGuide Systems

Series C in 2006
NeoGuide Systems Inc. develops robotic endoscopic technology for natural orifice transluminal endoscopic surgery. Its technology is used in colonoscopy application to provide access to abdominal and thoracic cavities. The company was founded in 2000 and is based in San Jose, California.

Pelikon

Series E in 2005
Pelikon, Ltd. provides morphing keypad solutions. It offers animated backlites and panels, as well as display products. The company also provides liquid crystal displays, display drivers, and display controllers. Its products are used in various applications, such as portable devices, home appliances, control panels, fitness equipment, and mobile phones. Pelikon, Ltd. was formerly known as Elumin, Ltd. The company was incorporated in 1999 and is based in Cambridge, the United Kingdom. It has sales offices in North America, China, and Japan. As of December 10, 2008, Pelikon Ltd. operates as a subsidiary of Multi-Fineline Electronix Singapore Pte., Ltd.

moveme.com

Venture Round in 2008
Moveme.com is a web site that provides free, instant quotes for moving related services.

Tridek-One

Venture Round in 2019
Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and give them a better life.

Pelikon

Series B in 2002
Pelikon, Ltd. provides morphing keypad solutions. It offers animated backlites and panels, as well as display products. The company also provides liquid crystal displays, display drivers, and display controllers. Its products are used in various applications, such as portable devices, home appliances, control panels, fitness equipment, and mobile phones. Pelikon, Ltd. was formerly known as Elumin, Ltd. The company was incorporated in 1999 and is based in Cambridge, the United Kingdom. It has sales offices in North America, China, and Japan. As of December 10, 2008, Pelikon Ltd. operates as a subsidiary of Multi-Fineline Electronix Singapore Pte., Ltd.

Santarus

Series D in 2003
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

Avila Therapeutics

Venture Round in 2010
Avila Therapeutics, Inc. designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics, Inc. has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics, Inc. operates as a subsidiary of Celgene Corporation.

Rhytec

Venture Round in 2004
Rhytec develops and markets skin treatment solutions. The company provides skin rejuvenation and regeneration technologies for treatment of wrinkles, scars, and skin discoloration. It markets its products under Portrait brand name. The company caters to dermatological, plastic, and cosmetic surgery sectors. It was founded in 2004 and is based in Waltham, Massachusetts. Rhytec, Inc. is a subsidiary of Rhytec, Ltd.

NeoGuide Systems

Series B in 2003
NeoGuide Systems Inc. develops robotic endoscopic technology for natural orifice transluminal endoscopic surgery. Its technology is used in colonoscopy application to provide access to abdominal and thoracic cavities. The company was founded in 2000 and is based in San Jose, California.

Cardiokine

Series B in 2006
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.

404 Found!

Series A in 2000
404 Found offered customer relationship management services and software, and online marketing. The company ended its operations in 2002 in the aftermath of the bubble burst. At its peak, 404 Found! operated in France, Italy, Spain, Germany and the UK. The company helped start ups to define their Internet strategy and operational deployment by conducting sectoral studies, competing positioning, schedule of conditions, etc. In 2001, the consulting division of 404 Found! was acquired by Deloitte & Touche.

Am-Beo

Series B in 2002
Am-Beo is a global provider of real-time rating and settlement solutions for the communications and next-generation services industry. Am-Beo's flagship product, rate-rec(TM), provides rating and revenue settlement for voice, data, content and other usage-based services. Am-Beo also provides Roam Manager(TM) for inter-carrier roaming agreements and settlements.

Ampla Pharmaceuticals

Venture Round in 2011
Ampla Pharmaceuticals designs and develops biopharmaceutical drugs. The company was incorporated in 2006 and is based in La Jolla, California.

Wisair

Series D in 2008
Wisair is a fabless semiconductor company providing single-chip based Ultra Wideband (UWB) and Wireless USB solutions for personal computing, consumer electronics, and mobile devices.

Ubiquisys

Series B in 2007
Ubiquisys is a mobile communications company that designs and develops communications devices for mobile operators and consumers. It provides ZoneGate femtocell system, a small plug-and-play device that plugs into home or office broadband connection and provides 3G coverage in the home and office, as well as supports various mobile services. The company also offers convergence solutions to the wireless-wireline convergence technology market.

NeRRe Therapeutics

Series A in 2012
NeRRe Therapeutics Ltd. develops preclinical and clinical neurokinin (NK) receptor antagonists. The company focuses on NK-1 antagonist asset orvepitant as an oral treatment for intense pruritus induced by targeted anti-cancer therapies. It offers NT-814, a NK-1, 3 antagonist; NT-949, a Phase I ready NK-1 antagonist; and NT-432, a NK-1 antagonist clinical candidate. The company was founded in 2012 and is based in Stevenage, United Kingdom.

The Fizzback Group

Series B in 2009
The Fizzback Group are innovators in customer engagement. Founded in 2004, the award-winning Fizzback solution helps companies to listen, respond, and act in real-time to their customers' comments. Feedback captured at the point of experience is analyzed automatically using a unique artificial intelligence engine, driving relevant responses, prompting company action and providing powerful insight into the voice of a previously silent majority. Fizzback enables businesses to derive true economic benefits by increasing customer lifetime value and positive word-of-mouth.

Farfetch

Series C in 2013
Farfetch operates an e-commerce website that unites various independent fashion boutiques. It offers bags, coats, dresses, jackets, jewellery, swimwear, trouser, shoes, knitwear, suits, shorts, and accessories. They operate a modular end-to-end technology platform purpose built to connect the luxury fashion ecosystem worldwide. Their vision was to create a single operating system that could address the complex demands of consumers and luxury sellers alike. Their platform is built on an API-enabled proprietary technology stack, which provides the foundation for the three main components: applications, services and data. Farfetch serves women, men, and kids. Jose Neves founded the company in 2008, with its headquarters in London, United Kingdom.

Moximed

Series C in 2017
Moximed, Inc. develops a joint preserving option for patients with knee osteoarthritis. The company offers Atlas System, an implantable joint unloader that works like a shock absorber for a patient with medial compartment knee osteoarthritis, or suffering from pain on the medial (inner) side of the knee, or desire to maintain high activity or productivity levels. It serves patients and medical professionals worldwide. Moximed, Inc. was formerly known as ExploraMed NC4, Inc. The company was incorporated in 2006 and is based in Hayward, California.

4-Antibody AG

Series A in 2007
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.

GMP Orphan

Series A in 2015
gmp-orphan (GMPO), it is their mission to identify, develop and provide access to innovative treatments to patients with rare diseases. Their experienced pharmaceutical development and commercial team in the field of rare diseases is critical in advancing this mission.

PrismTech

Series A in 2000
PrismTech is a provider of software platforms and tools for the Internet of Things, Industrial Internet and advanced wireless communications. PrismTech's products and services include: Vortex - Intelligent Data Sharing Platform for Business Critical Internet of Things (IoT) applications. Combining deterministic data delivery, system-wide data sharing and support for data analytics, Vortex helps system integrators, OEMs, device platform vendors and Cloud service providers (SaaS, PaaS and DaaS) deliver 'Smart' solutions for many vertical markets, including: Healthcare, Energy, Transportation, Smart Cities and Industrial Automation. Vortex provides efficient, secure and interoperable real-time Device to Device (D2D) and Device to Cloud information sharing. It is a key enabler for systems that have to reliably and securely deliver high volumes of real-time data with stringent end-to-end qualities-of-service (QoS). http://www.prismtech.com/vortex Spectra - Software Defined Radio (SDR) and Software Communications Architecture (SCA) solutions: Spectra CX a model-driven development tool that simplifies, accelerates, and validates the SDR/SCA development process; Spectra CF a high performance, low footprint, COTS SCA Core Framework; Spectra CDB a fully integrated and optimized SDR middleware stack running across a wide range of FPGA, DSP and GPP processing elements; Spectra DTP - a wideband, high performance, baseband and RF SDR Development and test platform. http://www.prismtech.com/spectra DDS Community - an open source implementation of the OMG Data Distribution Service for Real-Time Systems (DDS) standard. DDS Community has experienced swift adoption in a variety of application domains characterized by the need to distribute high volumes of data with predictable low Haber latencies, such as, Radar Processors, Flying and Land Drones, Combat Management Systems, Air Traffic Management, High Performance Telemetry, Large Scale Supervisory Systems, and Automated Stocks and Options Trading. http://www.prismtech.com/dds-community The company was founded by Keith Steele in 1992 and is headquartered in Boston, Massachusetts. It has operations in Boston, Massachusetts, as well as in the United Kingdom, the Netherlands, and France. PrismTech Corporation operates as a subsidiary of PrismTech Holdings Ltd.
Capella Bioscience Limited engages in the discovery and development of monoclonal antibodies (mAbs). It focuses on the employment of proprietary technologies to discover, develop, and commercialize medicines based on mAbs therapeutics for oncology, autoimmune, and other diseases independently, as well in collaboration with biotechnology and academic partners. The company was founded in 2014 and is based in London, United Kingdom.

OpenCloud Limited

Series B in 2008
OpenCloud, formed in 2000 is a privately funded company. It provides the telecommunications industry with a real-time Application Server for agile development, deployment and efficient management of person-to-person communications services across current and next generation network technology.

Ubiquisys

Venture Round in 2010
Ubiquisys is a mobile communications company that designs and develops communications devices for mobile operators and consumers. It provides ZoneGate femtocell system, a small plug-and-play device that plugs into home or office broadband connection and provides 3G coverage in the home and office, as well as supports various mobile services. The company also offers convergence solutions to the wireless-wireline convergence technology market.

Qype

Series A in 2008
Qype is a social network based around user reviews of businesses and places. The site allows its users to browse a database of locations and see at a glance those which have been most favorably rated by the community. Members of the site can add new places to the existing database, rate and review businesses, add videos and photos and engage with the community via message boards, groups and messaging. Founded in 2005 by German entrepreneur Stephan Uhrenbacher, the site also has a mobile version which can enables users to locate the top rated place near to a specified location.

Iterum Therapeutics plc

Series B in 2017
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Citel Technologies

Venture Round in 2004
Citel is The VoIP Migration Company™. They develop the world’s most comprehensive portfolio of network-edge products enabling enterprises to realize the cost and productivity benefits of IP telephony, while leveraging existing telecom and datacom investments. Founded in 1995 in Nottingham, UK as a developer of computer telephony integration (CTI) applications, the company has grown over the last decade to become a global leader in the design and manufacture of IP telephony migration solutions.

PowderMed

Series A in 2004
PowderMed developed vaccines for the treatment of chronic infectious diseases and cancer. The company used DNA coated gold particles delivered by a needle-free injection device to stimulate a powerful and specific T cell immune response.

Biocartis Group NV

Series B in 2010
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.

Pathwork Diagnostics

Venture Round in 2006
Pathwork Diagnostics is based in Redwood City, California. The company develops and delivers innovative molecular diagnostics for oncology. The Pathwork Tissue of Origin Test for frozen tissue was the first to receive FDA clearance for a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastic cancer.